Literature DB >> 16406766

Transcending the biomarker mindset: deciphering disease mechanisms at the single cell level.

Erika A Danna1, Garry P Nolan.   

Abstract

The application of proteomics to disease research promises to enhance the understanding and treatment of many human maladies through the identification of molecular profiles associated with each disease. However, although much is made of the utility of molecular signatures as markers of disease state, insufficient emphasis is often placed on the simultaneous need for biological mechanism inquiry. Focused and detailed analyses of disease-associated signaling networks have the potential to be more mechanistically informative than large-scale proteomic profiling approaches, providing insight into the cellular processes involved in pathogenesis, disease progression and therapeutic resistance; while still providing diagnostic or clinical management direction. Phospho-specific flow cytometry provides a method for the analysis of pathological signaling networks, enabling the investigation of disease mechanisms at the single-cell level.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16406766     DOI: 10.1016/j.cbpa.2005.12.021

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  11 in total

1.  SlipChip for immunoassays in nanoliter volumes.

Authors:  Weishan Liu; Delai Chen; Wenbin Du; Kevin P Nichols; Rustem F Ismagilov
Journal:  Anal Chem       Date:  2010-04-15       Impact factor: 6.986

2.  Microarray methods for protein biomarker detection.

Authors:  Hye Jin Lee; Alastair W Wark; Robert M Corn
Journal:  Analyst       Date:  2008-06-05       Impact factor: 4.616

Review 3.  A systems biology approach to defining metastatic biomarkers and signaling pathways.

Authors:  Natalie E Goldberger; Kent W Hunter
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2009 Jul-Aug

4.  Characterization of cell lysis events on a microfluidic device for high-throughput single cell analysis.

Authors:  Amy D Hargis; Jean Pierre Alarie; John Michael Ramsey
Journal:  Electrophoresis       Date:  2011-10-25       Impact factor: 3.535

5.  Tyramide signal amplification for analysis of kinase activity by intracellular flow cytometry.

Authors:  Matthew R Clutter; Garrett C Heffner; Peter O Krutzik; Kacey L Sachen; Garry P Nolan
Journal:  Cytometry A       Date:  2010-11       Impact factor: 4.355

6.  BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.

Authors:  William E Pierceall; Steven M Kornblau; Nicole E Carlson; Xuelin Huang; Noel Blake; Ryan Lena; Michael Elashoff; Marina Konopleva; Michael H Cardone; Michael Andreeff
Journal:  Mol Cancer Ther       Date:  2013-10-03       Impact factor: 6.261

7.  Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia.

Authors:  David B Rosen; Santosh Putta; Todd Covey; Ying-Wen Huang; Garry P Nolan; Alessandra Cesano; Mark D Minden; Wendy J Fantl
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

Review 8.  Toxicity testing in the 21 century: defining new risk assessment approaches based on perturbation of intracellular toxicity pathways.

Authors:  Sudin Bhattacharya; Qiang Zhang; Paul L Carmichael; Kim Boekelheide; Melvin E Andersen
Journal:  PLoS One       Date:  2011-06-20       Impact factor: 3.240

9.  Multiparameter flow cytometry: advances in high resolution analysis.

Authors:  Erika A O'Donnell; David N Ernst; Ravi Hingorani
Journal:  Immune Netw       Date:  2013-04-30       Impact factor: 6.303

10.  Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches.

Authors:  Sudin Bhattacharya; Lisl K M Shoda; Qiang Zhang; Courtney G Woods; Brett A Howell; Scott Q Siler; Jeffrey L Woodhead; Yuching Yang; Patrick McMullen; Paul B Watkins; Melvin E Andersen
Journal:  Front Physiol       Date:  2012-12-14       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.